SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 116 filers reported holding SYNAGEVA BIOPHARMA CORP in Q1 2014. The put-call ratio across all filers is 2.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2015 | $568,000 | -37.0% | 5,825 | -40.1% | 0.01% | -33.3% |
Q4 2014 | $902,000 | +25.5% | 9,725 | -7.0% | 0.02% | +15.4% |
Q3 2014 | $719,000 | -56.5% | 10,455 | -33.6% | 0.01% | -53.6% |
Q2 2014 | $1,651,000 | +26.3% | 15,755 | 0.0% | 0.03% | +21.7% |
Q1 2014 | $1,307,000 | – | 15,755 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Baker Brothers Advisors | 11,660,432 | $1,137,242,000 | 9.46% |
BB BIOTECH AG | 1,025,476 | $100,015,000 | 2.98% |
EMORY UNIVERSITY | 9,854 | $961,000 | 1.82% |
COLUMBIA WANGER ASSET MANAGEMENT LLC | 3,245,542 | $316,538,000 | 1.72% |
New Leaf Venture Partners, L.L.C. | 24,379 | $2,378,000 | 1.61% |
Alpha Wave Global, LP | 304,000 | $29,649,000 | 1.46% |
Opus Point Partners Management, LLC | 17,700 | $1,726,000 | 1.45% |
SECTORAL ASSET MANAGEMENT INC | 365,684 | $35,665,000 | 1.35% |
Pier Capital, LLC | 61,028 | $5,952,000 | 0.90% |
Tekla Capital Management LLC | 198,689 | $19,378,000 | 0.77% |